Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post on LinkedIn:
“This paper suggests HE4 is not inferior to CA125 for monitoring ovarian cancer patients on PARPis-and maybe slightly more accurate (89.4% vs 79.1%).
Interesting? Yes. Practice-changing? Not really.
A small rise in HE4-like CA125-doesn’t justify changing a therapy that’s working. At most, it might anticipate imaging and push us toward PET or abdominal MRI instead of CT scan.
Meanwhile:
- higher costs.
- more tests without clear decision impact.
- more patient anxiety. Anyone who follows these patients knows how even a minimal fluctuation in CA125 can generate distress. Introducing another marker risks amplifying that fear-without offering a clear clinical benefit.
So yes, HE4 may be ‘not inferior.’ But not inferior does not mean useful.
If we are really looking for tools that can guide when to stop PARP inhibitors and who is relapsing biologically before radiology, then the future is likely elsewhere.
ctDNA is where the real shift will happen.”
Title: The utility of the novel biomarker HE4 for monitoring epithelial ovarian cancer during PARP inhibitor treatment
Authors: Alexandra Morella, Anne Stoklosa, Alexandra Blackman, Youngeun Armbuster, Rachael Rowswell-Turner, M. Craig Miller, Richard G. Moore
Read The Full Article
Other articles about Ovarian Cancer on OncoDaily.